The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
UNIRAD: Multicenter, double-blind, phase III study of everolimus plus ongoing adjuvant therapy in ER+, HER2- breast cancer.
Thomas Denis Bachelot
Employment or Leadership Position - Novartis
Honoraria - Novartis
Research Funding - Novartis
Sylvie Chabaud
No relevant relationships to disclose
Anne-Laure Martin
No relevant relationships to disclose
J Lemonnier
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Fabrice Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis